News

MindRhythm's EPISODE-PS Initial Trial Results are Published

MindRhythm Inc, in partnership with Wayne State University School of Medicine in Detroit, Michigan, today announces the first publication of results from the hEadPulse for Ischemic StrOke DEtection Prehospital Study (EPISODE-PS) trial. MyndRhythm Inc., was co-founded by UCSF researcher Dr. Wade...

Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal

Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, announced today that it has secured $7 million in seed financing. We congratulate the UCSF researchers, Matthias Hebrok, Mark Anderson, and Audrey Parent, on...

Nested Therapeutics Announces Nomination of First Development Candidate, a Potential First-in-Class Inhibitor of the RAS/MAPK Pathway

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers that were founded on the technology discovered by University researcher Kevan Shokat, PhD, today announced the nomination of the company’s first drug development...

Chroma Medicine Secures $135M in Series B Financing

Chroma, a genomic medicine company pioneering single-dose epigenetic editing therapeutics founded on UCSF research discovered by Luke Gilbert, PhD, and Jonathan Weissman, PhD., today announced the completion of a $135 million Series B financing. The financing will support the advancement of Chroma'...

MindRhythm Initiates Pivotal Portion of Prehospital Stroke Trial

MindRhythm in partnership with Wayne State University School of Medicine in Detroit, Michigan, today announces the conclusion of phase I and initiation of the pivotal portion of its hEadPulse for Ischemic StrOke DEtection Prehospital Study (EPISODE-VS). MindRhythm was co-founded by UCSFs Dr. Wade...

The University of California and Foundery Sign Master Agreement to Translate Novel Discoveries into Transformational Immunotherapies

The unique industry-academic partnership supports UCSF investigator research while creating opportunities for downstream drug development and shared economics. MORE

Long-term functional regeneration of radiation-damaged salivary glands through delivery of a neurogenic hydrogel

Patients battling certain forms of cancer may find their salivary glands are severely depleted after radiotherapy. With no regenerative therapies available, organ dysfunction is irreversible. UCSF professors Chelsea Bahney and Sarah Knox present in 'Science,' their research into neurogenic...

Barry Selick Moves From UCSF To Hinge Bio

Barry Selick, Ph.D., successful biopharmaceutical scientist, senior executive, and entrepreneur, appointed Chief Executive Officer at Hinge Bio.

Rezo Therapeutics to Emerge from Stealth

The team behind Rezo Therapeutics, a new biotech co-founded by a group of University of California, San Francisco, scientists including Natalia Jura, Kevan Shokat, Nevan Krogan, and industry veterans George Scangos and Norbert Bischofberger, was weighing if, and how, to finally come out of stealth...

Increasing the success potential of promising biotech companies

Biotech startups benefit society by solving unmet scientific and medical needs, but more can be done to move their technologies to market more quickly. This month, Program Director Stephanie Marrus of the University of California, San Francisco's Global Entrepreneurship Program, together with John...